PMID- 20557362
OWN - NLM
STAT- MEDLINE
DCOM- 20100920
LR  - 20220316
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 15
IP  - 3
DP  - 2010 Jun
TI  - The effect of probiotics and mucoprotective agents on PPI-based triple therapy 
      for eradication of Helicobacter pylori.
PG  - 206-13
LID - 10.1111/j.1523-5378.2010.00751.x [doi]
AB  - BACKGROUND/AIMS: Recent studies have found that probiotics have anti-Helicobacter 
      pylori (HP) properties. We evaluated the additive effects of (i) Saccharomyces 
      boulardii combined with proton pump inhibitor (PPI)-based triple therapy and (ii) 
      S. boulardii and a mucoprotective agent (DA-9601) coupled with PPI-based triple 
      therapy for HP eradication. METHODS: We recruited 991 HP infected patients and 
      randomized them into one of three groups, (A) PPI-based 7-day triple therapy, (B) 
      the same triple therapy plus S. boulardii for 4 weeks, and (C) the same 7-day 
      triple therapy plus S. boulardii and mucoprotective agent for 4 weeks. All 
      patients in the three groups were tested via (13)C-urea breath test 4 weeks after 
      the completion of the therapy. RESULTS: According to the results of an 
      intention-to-treat analysis, HP eradication rates for the groups A, B, and C were 
      71.6% (237/331), 80.0% (264/330), and 82.1% (271/330), respectively (p = .003). 
      According to the results of a per protocol analysis, the eradication rates were 
      80.0% (237/296), 85.4% (264/309) and, 84.9% (271/319), respectively (p = .144). 
      The frequency of side effects in group B (48/330) and C (30/330) was lower than 
      that in group A (63/331) (p < .05). CONCLUSION: This study suggests that 
      supplementation with S. boulardii could be effective for improving HP eradication 
      rates by reducing side effects thus helping completion of eradication therapy. 
      However, there were no significant effects on HP eradication rates associated 
      with the addition of mucoprotective agents to probiotics and triple therapy.
FAU - Song, Min Jun
AU  - Song MJ
AD  - Department of Internal Medicine and Kangbuk Samsung Hospital, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
FAU - Park, Dong Il
AU  - Park DI
FAU - Park, Jung Ho
AU  - Park JH
FAU - Kim, Hong Joo
AU  - Kim HJ
FAU - Cho, Yong Kyun
AU  - Cho YK
FAU - Sohn, Chong Il
AU  - Sohn CI
FAU - Jeon, Woo Kyu
AU  - Jeon WK
FAU - Kim, Byung Ik
AU  - Kim BI
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (DA 9601)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Plant Extracts)
RN  - 0 (Proton Pump Inhibitors)
RN  - 8W8T17847W (Urea)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breath Tests
MH  - Female
MH  - Gastrointestinal Agents/*administration & dosage/adverse effects
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori/*isolation & purification
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Plant Extracts/*administration & dosage/adverse effects
MH  - Probiotics/*administration & dosage/adverse effects
MH  - Proton Pump Inhibitors/*administration & dosage/adverse effects
MH  - Saccharomyces/*growth & development
MH  - Treatment Outcome
MH  - Urea/analysis
MH  - Young Adult
EDAT- 2010/06/19 06:00
MHDA- 2010/09/21 06:00
CRDT- 2010/06/19 06:00
PHST- 2010/06/19 06:00 [entrez]
PHST- 2010/06/19 06:00 [pubmed]
PHST- 2010/09/21 06:00 [medline]
AID - HEL751 [pii]
AID - 10.1111/j.1523-5378.2010.00751.x [doi]
PST - ppublish
SO  - Helicobacter. 2010 Jun;15(3):206-13. doi: 10.1111/j.1523-5378.2010.00751.x.